Journal article
Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer
RS Eapen, SG Williams, S Macdonald, SP Keam, N Lawrentschuk, L Au, MS Hofman, DG Murphy, PJ Neeson
Nature Reviews Urology | NATURE PORTFOLIO | Published : 2024
Abstract
High-risk localized prostate cancer remains a lethal disease with high rates of recurrence, metastases and death, despite attempts at curative local treatment including surgery. Disease recurrence is thought to be a result of failure of local control and occult micrometastases. Neoadjuvant strategies before surgery have been effective in many cancers, but, to date, none has worked in this setting for prostate cancer. Prostate-specific membrane antigen (PSMA)-based theranostics is an exciting and rapidly evolving field in prostate cancer. The novel intravenous radionuclide therapy, [177Lu]Lu-PSMA-617 (lutetium PSMA) has been shown to be effective in treating men with metastatic castration-res..
View full abstractGrants
Awarded by Prostate Cancer Foundation
Funding Acknowledgements
The authors acknowledge support from the Prostate Cancer Foundation through their Young Investigator Award. The LuTectomy trial was funded by the Movember Foundation, the Australian Government Medical Research Future Fund (MRFF) with contribution from the EJ Whitten Foundation and Novartis. PSMA-617 was supplied by Novartis and no carrier added 177 Lu by the Australian Nuclear Science and Technology Organisation (ANSTO). Finally, they thank the patients who participated in the LuTectomy clinical trial and the staff involved in the study from numerous departments at the Peter MacCallum Cancer Centre, Melbourne.